MLLT10

Across TCGA pan-cancer cohorts, MLLT10 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MLLT10 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MLLT10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MLLT10 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where MLLT10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.219	0.691	.001	37	view →
LSCC	OS	Tertile	All	0.886	0.643	.017	8	view →
HNSC	OS	Quartile	II,III,IV	0.643	1.000	.040	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MLLT10–PDAC (OS)

Open the PDAC breakdown →